Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 27 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine if baseline subgroups in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial can be identified for whom intensive compared with standard glycemia treatment had different effects on all-cause mortality. RESEARCH DESIGN AND METHODS: Exploratory post hoc intention-to-treat comparisons were made between intensive and standard glycemia groups on all-cause mortality by subgroups defined by baseline characteristics. RESULTS: There were few significant interactions between baseline characteristics and effects of intensive versus standard glycemia treatment on mortality: self-reported history of neuropathy (hazard ratio [HR] 1.95, 95% CI 1.41–2.69) versus no history of neuropathy (0.99, 0.79–1.26; P value for interaction 0.0008), higher A1C (A1C >8.5%: HR 1.64, 95% CI 1.22–2.22; A1C 7.5–8.4%: 1.00, 0.75–1.34; A1C <7.5%: 1.00, 0.67–1.50; P value for interaction 0.04), and aspirin use (HR 1.45, 95% CI 1.13–1.85, compared with 0.96, 0.72–1.27, in nonusers; P value for interaction 0.03). CONCLUSIONS: We found a remarkable similarity of effect from intensive compared with standard glycemia treatment on mortality across most baseline subgroups. No differential effect was found in subgroups defined by variables anticipated to have an interaction: age, duration of diabetes, and previous history of cardiovascular disease. The three baseline characteristics that defined subgroups for which there was a differential effect on mortality may help identify patients with type 2 diabetes at higher risk of mortality from intensive regimens for glycemic control. Further research is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“Adding to the controversy were results of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial (VADT), demonstrating that although there was no significant reduction in the primary end point of CVD events, there was no increase in mo…”
ResultHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“Adding to the controversy were results of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial (VADT), demonstrating that although there was no significant reduction in the primary end point of CVD events, there was no increase in mo…”
ResultStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“Analyses were conducted using intention-to-treat comparisons between the intensive glycemia and standard groups on the mortality rate within each subgroup as defined in Table 1 above (15).”
MethodFeldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293 · cited 1×
“Complete details of the study design and conduct have been previously published (13,14).”
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661 · cited 1×
“Complete details of the study design and conduct have been previously published (13,14).”
Affner, S. T. M. H., Ehto, S. E. L., Önnemaa, T. A. R., Yörälä, K. A. P., & Aakso, M. A. L. (1998) · Cited by 480
Sacco, M., Pellegrini, F., Roncaglioni, M. C., Avanzini, F., Tognoni, G., Nicolucci, A., & on behalf of the PPP Collaborative Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3264 · Cited by 381
Intensive Glycemic Control in the ACCORD and ADVANCE Trials
Dluhy, R. G., & McMahon, G. T. (2008) · New England Journal of Medicine · doi:10.1056/nejme0804182 · Cited by 378
Lowe, L. P., Liu, K., Greenland, P., Metzger, B. E., Dyer, A. R., & Stamler, J. (1997) · Diabetes Care · doi:10.2337/diacare.20.2.163 · Cited by 235
Long-Term Glycemic Control Relates to Mortality in Type II Diabetes
Andersson, D. K., & Svärdsudd, K. (1995) · Diabetes Care · doi:10.2337/diacare.18.12.1534 · Cited by 221
Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 Diabetes
Cusick, M., Meleth, A. D., Agrón, E., Fisher, M. R., Reed, G. F., Knatterud, G. L., Barton, F. B., Davis, M. D., Ferris, F. L., Chew, E. Y., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.617 · Cited by 196
Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?
Montori, V. M., & Fernández-Balsells, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00008 · Cited by 160
Eight to nine year mortality in known non-insulin dependent diabetics and controls
Damsgaard, E. M. S., Frøland, A., Jørgensen, O. D., & Mogensen, C. E. (1992) · Kidney International · doi:10.1038/ki.1992.114 · Cited by 132
Coppini, D. V., Bowtell, P., Weng, C., Young, P. J., & Sönksen, P. H. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00170-5 · Cited by 123 · cited 1×
“Peripheral neuropathy is a common complication of diabetes, and excess mortality has been related to diminished peripheral sensation (16,18), foot ulceration, and history of lowerextremity amputation (19).”
BackgroundMortality following lower extremity amputation in minorities with diabetes mellitus
Lavery, L. A., van Houtum, W. H., Armstrong, D. G., Harkless, L. B., Ashry, H. R., & Walker, S. C. (1997) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(97)00058-2 · Cited by 69 · cited 1×
“Peripheral neuropathy is a common complication of diabetes, and excess mortality has been related to diminished peripheral sensation (16,18), foot ulceration, and history of lowerextremity amputation (19).”
BackgroundThe ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus
Havas, S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.518 · Cited by 41 · cited 1×
“The finding of excess mortality in the intensive arm of the ACCORD trial has led to controversy about implementation of intensive glucose control in patients with type 2 diabetes (7,8).”
BackgroundIntensive Glycemic Control and Cardiovascular Disease Observations From the ACCORD Study
Cefalu, W. T., & Watson, K. E. (2008) · Diabetes · doi:10.2337/db08-0220 · Cited by 31
The benefit of aspirin therapy in type 2 diabetes: What is the evidence?
Sirois, C., Poirier, P., Moisan, J., & Grégoire, J. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.01.030 · Cited by 20 · cited 1×
“Although aspirin use is recommended for patients with type 2 diabetes (21), the evidence supporting its benefit is now being reconsidered (22).”
BackgroundENHANCE and ACCORD: Controversy over surrogate end points
Nissen, S. E. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0027-z · Cited by 6
Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial
Ogawa, H. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.218 · Cited by 5
Cited by
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Selvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
Metadata
- Authors
- Calles-Escandón, J., Lovato, L. C., Simons-Morton, D. G., Kendall, D. M., Pop-Busui, R., Cohen, R. M., Bonds, D. E., Fonseca, V. A., Ismail-Beigi, F., Banerji, M. A., Failor, A., & Hamilton, B.
- Affiliations
- Wake Forest University Health Sciences (US)
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland;
- Park Nicollet Health Services (US)
- Department of Endocrinology, Metabolism, and Nutrition, University of Michigan Medical School, Ann Arbor, Michigan;
- University of Cincinnati Medical Center (US)
- National Institutes of Health (US)
- Tulane University (US)
- VA Medical Center, Section of Endocrinology, University of Cleveland, Cleveland, Ohio;
- State University of New York (US)
- University of Washington (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Calles-Escandón, Jorge
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-01-26
- Volume
- 33
- Issue
- 4
- Pages
- 721-727
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2845012
- OpenAlex
- W2136749671
- Cited by
- 160
- References
- 28
- Citations by year
- 2026: 1 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 13 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 20 · 2014: 22 · 2013: 13 · 2012: 10
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, type 2 diabetes, all-cause mortality, subgroup analysis, HbA1c, aspirin use, cardiovascular risk, ACCORD trial, treatment effect heterogeneity
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.